About the re­designed End­points News

We’ve up­grad­ed the End­points web ex­pe­ri­ence for the first time since our launch three years ago. It was built from scratch in­ter­nal­ly with the read­er in mind to be a clean­er and more use­able plat­form. We have some spe­cif­ic goals in mind for the de­sign, which I’ll de­scribe be­low. And for those in­ter­est­ed, I’d like to go in­to some depth be­hind the over­all process and back­end be­hind End­points News.

But first, a word of thanks to the CRO Bio­rasi for their ex­clu­sive spon­sor­ship of the re­design. End­points’ chief rev­enue of­fi­cer Mike Peck and I met the team a year ago at a con­fer­ence, where we talked about clin­i­cal out­sourc­ing and its place in drug de­vel­op­ment. Soon, we de­vel­oped a brand cam­paign tied to the End­points brand re­fresh, and over the next two weeks you’ll see the re­sults of that across the site.

I set out three ma­jor goals for the re­design. They were:

  • In­crease the con­ver­sion rate of web vis­i­tors in­to ba­sic sub­scribers
  • In­crease the av­er­age num­ber of sto­ries read per vis­it
  • 2x im­prove­ment on the de­sign, fit, and fin­ish

The first two can be ob­jec­tive­ly mea­sured. And in the 48 hours since we soft launched the site, we’ve al­ready seen im­prove­ments. Im­prov­ing the rate at which new web vis­i­tors will­ing­ly and vol­un­tar­i­ly sub­scribe to get the ba­sic End­points email prod­uct is pure or­gan­ic growth and re­mains our #1 mar­ket­ing KPI. We crossed 50,000 re­cent­ly. Three years ago, John Car­roll and I kicked things off with around 1,000 per­son­al con­tacts who were our Day One sub­scribers. And in­creas­ing the av­er­age num­ber of sto­ries read per vis­it is a crit­i­cal mea­sure of the dis­cov­er­abil­i­ty of our news con­tent. We were av­er­ag­ing around 1.2 sto­ries per vis­i­tor. We ex­pect to triple that num­ber with this new de­sign.

The last goal — a 2x im­prove­ment in the de­sign — is a sub­jec­tive one. And to do it jus­tice re­quires a look that reach­es back to well be­fore the ori­gins of End­points News. I’ll do that be­low for the read­ers who are in­ter­est­ed.

For the rest, just know the de­sign was cre­at­ed with you, the read­er, in mind. End­points’ tech/de­sign team is deeply com­mit­ted to in­creas­ing the use­abil­i­ty of the web­site. And that goes dou­ble for our pre­mi­um sub­scribers (check out the new read­er pro­file fea­ture for a glimpse).

If you de­pend on End­points, but haven’t up­grad­ed to a pre­mi­um sub­scrip­tion — now is the time. Our En­ter­prise plan of­fer is a trans­par­ent, un­lim­it­ed seat-li­cense for com­pa­nies for a flat $1,000/year re­gard­less of head­count. And the In­sid­er plan is $200/year for in­di­vid­u­als. You can see all the ben­e­fits here.

Once again, thanks to Bio­rasi for their ex­clu­sive spon­sor­ship of End­points News dur­ing the #BIO2019 con­ven­tion. You’ll see their brand place­ments across the new plat­forms for the next two weeks, with a we­bi­nar launch­ing lat­er in the year. I en­cour­age you to check out their new web­site as well.

We hope you en­joy the new End­points ex­pe­ri­ence.


About the process and de­sign

John Car­roll de­scribed the ear­li­est days of End­points News re­cent­ly. It was a ful­ly boot­strapped ven­ture with four vir­tu­al em­ploy­ees.

Ty­pog­ra­phy com­par­i­son. Top: old ver­sion (Eq­ui­ty) / Bot­tom: new (Ivar Text)

Click on the im­age to see the full-sized ver­sion

Long­time read­ers know that John and I were at a pre­vi­ous com­pa­ny. And when we found­ed End­points, we knew it was go­ing to be a ful­ly boot­strapped ven­ture. We had a well-known ed­i­tor. And with tools like Word­Press, start­ing a me­dia com­pa­ny to­day is so easy, any­one can do it.

But there was no bud­get for a de­sign­er. So the task fell be­tween our CTO Ig­or Yavych and my­self. Frankly, we’re no de­sign­ers.

Com­par­i­son of the old End­ponts News home­page with the June 2019 up­grade

Click on the im­age to see the full-sized ver­sion

Last year, thanks to the suc­cess of our paid sub­scrip­tion cam­paigns, we were able to start build­ing out our team. We brought on board Valentin Manov as our cre­ative di­rec­tor, and the new fit and fin­ish you see to­day are his con­tri­bu­tions.

It was vi­tal­ly im­por­tant to me that once we had a de­sign bud­get, we would make “good de­sign” an in­ter­nal ca­pa­bil­i­ty — not some­thing we’d out­source. When de­sign­ers have ac­cess to the on­line news­room, they get to see what’s im­por­tant to ed­i­tors and that in turn shapes their read­er-fac­ing work. We did not want to go to an out­side agency and ask for pitch­es on what they thought our news ex­pe­ri­ence ought to be.

Back in March, I flew to Sofia, Bul­gar­ia to meet up with Valentin and Ig­or and fi­nal­ize the ba­sic out­lines of the de­sign you see to­day. We named this re­lease “Rakia,” which is the most pop­u­lar brandy in the Balka­ns.

We’re ea­ger to know what you think about the de­sign.

PS: In or­der to em­brace the newest tech­nolo­gies that are com­ing, we had to end sup­port of some very old web browsers. Old­er ver­sions of In­ter­net Ex­plor­er are no longer sup­port­ed: If you’re on a PC, Mi­crosoft’s Edge brows­er is ex­cel­lent. Ig­or rec­om­mends the Opera Brows­er. My rec­om­men­da­tion? The lat­est ver­sion of Chrome will al­ways do.

Susan Galbraith, AstraZeneca EVP, oncology R&D, at EUBIO22 (Rachel Kiki for Endpoints News)

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

Right from the start, the execs at Neogene had some lofty goals in mind when they decided to try their hand at a cell therapy that could tackle solid tumors.

Its founders have helped hone a new approach that would pack in multiple neoantigen targets to create a personalized TCR treatment that would not just make the leap from blood to solid tumors, but do it with durability. And they managed to make their way rapidly to the clinic, unveiling their first Phase I program for advanced tumors just last May.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Tim Van Hauwermeiren, argenx CEO

Ar­genx pur­chas­es $100M+ FDA pri­or­i­ty re­view vouch­er from blue­bird bio

Argenx’s Vyvgart is due for a speedy review at the FDA, thanks to a $102 million priority review voucher (PRV).

The Netherland-based biotech picked up the PRV from bluebird bio, the companies announced on Wednesday. PRVs shorten a drug’s FDA review period from 10 months to 6 months, though they often sell on the open market for around $100 million each.

Argenx plans on using the express ticket on efgartigimod, its neonatal Fc receptor (FcRn) blocker marketed as Vyvgart for adults with generalized myasthenia gravis (gMG). While Vyvgart won its first approval last December for the chronic neuromuscular disease — which is characterized by difficulties with facial expression, speech, swallowing and breathing — CEO Tim Van Hauwermeiren said in a news release that he plans to “be active in fifteen disease targets by 2025.”

Ei­sai’s ex­pand­ed Alzheimer’s da­ta leave open ques­tions about safe­ty and clin­i­cal ben­e­fit

Researchers still have key questions about Eisai’s investigational Alzheimer’s drug lecanemab following the publication of more Phase III data in the New England Journal of Medicine Tuesday night.

In the paper, which was released in conjunction with presentations at an Alzheimer’s conference, trial investigators write that a definition of clinical meaningfulness “has not been established.” And the relative lack of new information, following topline data unveiled in September, left experts asking for more — setting up a potential showdown to precisely define how big a difference the drug makes in patients’ lives.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi and DN­Di aim to elim­i­nate sleep­ing sick­ness in Africa with promis­ing Ph II/III re­sults for new drug

The Drugs for Neglected Diseases initiative (DNDi) and Sanofi today said that their potential sleeping sickness treatment saw success rates of up to 95% from a Phase II/III study investigating the safety and efficacy of single-dose acoziborole.

The potentially transformative treatment for sleeping sickness would mainly be targeted at African countries, according to data published today in The Lancet Infectious Diseases medical journal. The clinical trial was led by DNDi and its partners in the Democratic Republic of the Congo (DRC) and Guinea, with the authors noting:

Lil­ly's Covid-19 mAb no longer au­tho­rized due to Omi­cron sub­vari­ants, FDA says

The FDA on Wednesday announced that Eli Lilly’s Covid-19 drug bebtelovimab is no longer authorized to treat Covid-19 because of the rising numbers of two new subvariants that the drug does not work against.

The Centers for Disease Control and Prevention last week published new estimates that the combined proportion of Covid-19 cases caused by the Omicron subvariants BQ.1 and BQ.1.1 are greater than 57% nationally, and already above 50% in all individual regions but one.

Illustration: Assistant Editor Kathy Wong for Endpoints News

Twit­ter dis­ar­ray con­tin­ues as phar­ma ad­ver­tis­ers ex­tend paus­es and look around for op­tions, but keep tweet­ing

Pharma advertisers on Twitter are done — at least for now. Ad spending among the previous top spenders flattened even further last week, according to the latest data from ad tracker Pathmatics, amid ongoing turmoil after billionaire boss Elon Musk’s takeover now one month ago.

Among 18 top advertisers tracked for Endpoints News, only two are spending: GSK and Bayer. GSK spending for the full week through Sunday was minimal at just under $1,900. Meanwhile, German drugmaker Bayer remains the industry outlier upping its spending to $499,000 last week from $480,000 the previous week. Bayer’s spending also marks a big increase from a month ago and before the Musk takeover, when it spent $16,000 per week.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Vi­a­tris with­draws ac­cel­er­at­ed ap­proval for top­i­cal an­timi­cro­bial 24 years lat­er

After 24 years without confirming clinical benefit, the FDA announced Tuesday morning that Viatris (formed via Mylan and Pfizer’s Upjohn) has decided to withdraw a topical antimicrobial agent, Sulfamylon (mafenide acetate), after the company said conducting a confirmatory study was not feasible.

Sulfamylon first won FDA’s accelerated nod in 1998 as a topical burn treatment, with the FDA noting that last December, Mylan told the agency that it wasn’t running the trial.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.

Emily Leproust, Twist Bioscience CEO

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

The synthetic DNA manufacturer Twist Bioscience has given a peek behind the curtain to several analysts into its “factory of the future” as well as insight into the cost structure, workflow and technology at the site.

The 110,000-square-foot manufacturing site in the city of Wilsonville, OR, just south of Portland, which was announced back in 2020, will double Twist’s production capacity and bring around 400 jobs to the area.

Lex­i­con slams FDA over hear­ing de­nial fol­low­ing a CRL for its SGLT2 in­hibitor can­di­date

Lexicon Pharmaceutical is not giving up on its Type I diabetes candidate, despite FDA’s repeated rejections. This week the company laid out is argument again for a hearing on sotagliflozin in response to the FDA’s most recent denial.

The issue goes back to March 2019 when the FDA made very clear to Lexicon and its now departed partner Sanofi that it would not approve their application for a potential Type I diabetes drug because it does not appear to be safe.